Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphomaLaura Samples, Mazyar Shadman, Frederick L. Locke et al.|Blood|2025Cited by 15
Development and validation of predictive models of early immune effector cell–associated hematotoxicityEmily C. Liang, Jordan Gauthier, Jennifer J. Huang et al.|Blood Advances|2024Cited by 11
Real-World Comparison of Lisocabtagene Maraleucel (Liso-Cel) and Axicabtagene Ciloleucel (Axi-Cel): Efficacy & ToxicityAndrew J. Portuguese, Jordan Gauthier, Aya Albittar et al.|Transplantation and Cellular Therapy|2024Cited by 9
Real-world comparison of lisocabtagene maraleucel and axicabtagene ciloleucel in large B-cell lymphoma: an inverse probability of treatment weighting analysis with 3-year follow upAndrew J. Portuguese, Jordan Gauthier, Jennifer J. Huang et al.|Haematologica|2025Cited by 4
Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel: Efficacy and Toxicity in a Real-World SettingAndrew J. Portuguese, Jordan Gauthier, Aya Albittar et al.|Blood|2023Cited by 3